GlaxoSmithKline (GSK) Financial Analysis & Valuation | Quarter Chart
GlaxoSmithKline (GSK)
GSKPrice: $51.24
Fair Value: 🔒
🔒score
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Tota... more
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of va... more
Description
Shares
| Market Cap | $103.05B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | GB | CEO | Luke Victor Miels |
| IPO Date | 1980-03-28 | CAGR | 0.08% |
| Employees | 68,629 | Website | www.gsk.com |
| Div. Yield | 3.5% | Payout Ratio | 0.45% |
| Buy Back Yield | 1.28% | Total Yield | 4.78% |
GSK chart loading...
Fundamentals
Technicals
| Enterprise Value | $104.25B | P/E Ratio | 13.41 |
| Forward P/E | 10.14 | PEG Ratio | 1.67 |
| P/S Ratio | 2.33 | P/B Ratio | 4.33 |
| P/CF Ratio | 10.22 | P/FCF Ratio | 15.24 |
| EPS | $3.82 | EPS Growth 1Y | 122.22% |
| EPS Growth 3Y | 48.67% | EPS Growth 5Y | 28.24% |
| Revenue Growth 1Y | 3.97% | Gross Margin | 0.73% |
| Operating Margin | 0.22% | Profit Margin | 0.18% |
| ROE | 0.36% | ROA | 0.09% |
| ROCE | 0.18% | Current Ratio | 0.79 |
| Quick Ratio | 0.52 | Cash Ratio | 0.15 |
| Debt/Equity | 1.07 | Interest Coverage | 10.37 |
| Altman Z Score | 1.66 | Piotroski Score | 7 |